These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37062866)

  • 1. Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation.
    Filippatos G; Farmakis D; Butler J; Zannad F; Ferreira JP; Ofstad AP; Iwata T; Brueckmann M; Pocock SJ; Packer M; Anker SD;
    Eur J Heart Fail; 2023 Jul; 25(7):970-977. PubMed ID: 37062866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post-hoc analysis of the ATHENA trial.
    Vaduganathan M; Piccini JP; Camm AJ; Crijns HJGM; Anker SD; Butler J; Stewart J; Braceras R; Albuquerque APA; Wieloch M; Hohnloser SH
    Eur J Heart Fail; 2022 Jun; 24(6):1094-1101. PubMed ID: 35293087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR-Reduced.
    Filippatos G; Anker SD; Butler J; Farmakis D; Ferreira JP; Gollop ND; Brueckmann M; Iwata T; Pocock S; Zannad F; Packer M;
    Eur J Heart Fail; 2022 Dec; 24(12):2297-2304. PubMed ID: 36194680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trial.
    Böhm M; Butler J; Mahfoud F; Filippatos G; Ferreira JP; Pocock SJ; Slawik J; Brueckmann M; Linetzky B; Schüler E; Wanner C; Zannad F; Packer M; Anker SD;
    Eur J Heart Fail; 2022 Oct; 24(10):1883-1891. PubMed ID: 36087309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
    Bhm M; Anker S; Mahfoud F; Lauder L; Filippatos G; Ferreira JP; Pocock SJ; Brueckmann M; Saloustros I; Schler E; Wanner C; Zannad F; Packer M; Butler J
    Eur Heart J; 2023 Feb; 44(5):396-407. PubMed ID: 36478225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of left ventricular ejection fraction in atrial fibrillation patients without pre-existing heart failure.
    Hamatani Y; Iguchi M; Minami K; Ishigami K; Esato M; Tsuji H; Wada H; Hasegawa K; Ogawa H; Abe M; Lip GYH; Akao M;
    ESC Heart Fail; 2023 Oct; 10(5):3091-3101. PubMed ID: 37604489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial.
    Butler J; Usman MS; Filippatos G; Ferreira JP; Böhm M; Brueckmann M; Januzzi JL; Kaul S; Piña IL; Ponikowski P; Senni M; Sumin M; Verma S; Zaremba-Pechmann L; Pocock SJ; Packer M; Anker S
    JAMA Cardiol; 2023 Jul; 8(7):640-649. PubMed ID: 37223933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced.
    Zannad F; Ferreira JP; Pocock SJ; Zeller C; Anker SD; Butler J; Filippatos G; Hauske SJ; Brueckmann M; Pfarr E; Schnee J; Wanner C; Packer M
    Circulation; 2021 Jan; 143(4):310-321. PubMed ID: 33095032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction.
    Linssen GC; Rienstra M; Jaarsma T; Voors AA; van Gelder IC; Hillege HL; van Veldhuisen DJ
    Eur J Heart Fail; 2011 Oct; 13(10):1111-20. PubMed ID: 21642293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Preserved trial.
    Sharma A; Ferreira JP; Zannad F; Pocock SJ; Filippatos G; Pfarr E; Petrini M; Kraus BJ; Wanner C; Packer M; Butler J; Anker SD
    Eur J Heart Fail; 2023 Aug; 25(8):1337-1348. PubMed ID: 37062851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin: A Review in Symptomatic Chronic Heart Failure.
    Frampton JE
    Drugs; 2022 Nov; 82(16):1591-1602. PubMed ID: 36374374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Implications of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved.
    Januzzi JL; Butler J; Zannad F; Filippatos G; Ferreira JP; Pocock SJ; Sattar N; Verma S; Vedin O; Iwata T; Brueckmann M; Packer M; Anker SD;
    JACC Heart Fail; 2022 Jul; 10(7):512-524. PubMed ID: 35670067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heart failure progression and mortality in atrial fibrillation patients with preserved or reduced left ventricular ejection fraction.
    Slee A; Saad M; Saksena S
    J Interv Card Electrophysiol; 2019 Sep; 55(3):325-331. PubMed ID: 30887281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction.
    Butt JH; Kondo T; Jhund PS; Comin-Colet J; de Boer RA; Desai AS; Hernandez AF; Inzucchi SE; Janssens SP; Kosiborod MN; Lam CSP; Langkilde AM; Lindholm D; Martinez F; Petersson M; Shah SJ; Thierer J; Vaduganathan M; Verma S; Wilderäng U; Claggett BC; Solomon SD; McMurray JJV
    J Am Coll Cardiol; 2022 Nov; 80(18):1705-1717. PubMed ID: 36041668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atrial fibrillation and risk of incident heart failure with reduced versus preserved ejection fraction.
    Nicoli CD; O'Neal WT; Levitan EB; Singleton MJ; Judd SE; Howard G; Safford MM; Soliman EZ
    Heart; 2022 Mar; 108(5):353-359. PubMed ID: 34031160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.
    Solomon SD; Vaduganathan M; Claggett BL; de Boer RA; DeMets D; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Belohlavek J; Chiang CE; Willem Borleffs CJ; Comin-Colet J; Dobreanu D; Drozdz J; Fang JC; Alcocer Gamba MA; Al Habeeb W; Han Y; Cabrera Honorio JW; Janssens SP; Katova T; Kitakaze M; Merkely B; O'Meara E; Kerr Saraiva JF; Tereschenko SN; Thierer J; Vardeny O; Verma S; Vinh PN; Wilderäng U; Zaozerska N; Lindholm D; Petersson M; McMurray JJV
    JACC Heart Fail; 2022 Mar; 10(3):184-197. PubMed ID: 35241246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.
    Butler J; Filippatos G; Siddiqi TJ; Ferreira JP; Brueckmann M; Bocchi E; Böhm M; Chopra VK; Giannetti N; Iwata T; Januzzi JL; Kaul S; Piña IL; Ponikowski P; Rauch-Kröhnert U; Shah SJ; Senni M; Sumin M; Verma S; Zhang J; Pocock SJ; Zannad F; Packer M; Anker SD
    Circulation; 2022 Oct; 146(14):1046-1055. PubMed ID: 36098051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the US.
    Talha KM; Butler J; Greene SJ; Aggarwal R; Anker SD; Claggett BL; Solomon SD; McMurray JJV; Vaduganathan M; Fonarow GC
    JAMA Cardiol; 2023 Jan; 8(1):66-73. PubMed ID: 36334258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Atrial Fibrillation on Mortality, Stroke Risk, and Quality-of-Life Scores in Patients With Heart Failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF]).
    Cherian TS; Shrader P; Fonarow GC; Allen LA; Piccini JP; Peterson ED; Thomas L; Kowey PR; Gersh BJ; Mahaffey KW
    Am J Cardiol; 2017 Jun; 119(11):1763-1769. PubMed ID: 28416199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER.
    Kondo T; Butt JH; Curtain JP; Jhund PS; Docherty KF; Claggett BL; Vaduganathan M; Bachus E; Hernandez AF; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Kosiborod MN; Desai AS; Køber L; Ponikowski P; Sabatine MS; Solomon SD; McMurray JJV
    Circ Heart Fail; 2023 Dec; 16(12):e010898. PubMed ID: 37886880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.